Summary
Only one of the provided claims is assessed against the supplied label excerpts (the hepatic decompensation/hepatotoxicity warning). The other claims about generic launch timing/patent/exclusivity are not addressed by the supplied prescribing information and cannot be verified or contradicted from the provided label text.
Category Scores
Accurate Statements
PROMACTA in combination with interferon and ribavirin increases the risk of hepatic decompensation in patients with chronic hepatitis C; PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity (with monitoring and discontinuation as recommended).
Supported by the user-provided label text in Section 1: “In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation [see Warnings and Precautions (5.1)]” and “PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended [see Warnings and Precautions (5.2)]”.
Unsupported Statements
A generic version of Promacta (eltrombopag) launch timing depends on patent and exclusivity dates.
No FDA-approved prescribing information content related to generic launch timing, patents, or exclusivity was provided in the prompt.
Actual generic marketing usually cannot start until legal barriers lift.
No label support was provided for statements about when generic marketing can start.
For Promacta, marketing generally requires expiration (or successful challenge) of relevant patents and any remaining regulatory exclusivities that would block approval or launch.
No label support was provided for statements about patent/regulatory exclusivity requirements for marketing.
If a generic has already launched, the 'launch date' would be the first commercial availability date in the U.S.
No label support was provided for definitions or operational criteria for 'launch date'.
Generic launch dates differ by country (e.g., U.S., EU, UK).
No label support was provided for cross-country differences in generic launch timing.
Contradictions
Important Omissions
No label-supported information was provided to assess generic launch timing claims (patents/exclusivity/country launch differences).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-relevant safety claim evaluated (hepatic decompensation/hepatotoxicity risk with monitoring/discontinuation) matches the supplied warning text. The remaining claims concern generic launch timing and do not directly address patient safety within the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are about generic launch timing/patents/exclusivity and cannot be evaluated against the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Limit label-based evaluation to statements that are present in the supplied prescribing information (e.g., warnings/precautions). Exclude or clearly label as non-label/externally sourced any assertions about generic launch timing, patent status, exclusivity, or country-to-country launch differences.